AMS is pleased to announce that its research and development plan was selected on June 26, 2026 for the Ministry of Economy, Trade and Industry (METI) FY2026 Growth-Oriented R&D Support Program for Small and Medium-sized Enterprises (Go-Tech Program), and that the Company received formal grant approval on August 31, 2026.
Through this program, AMS will work to resolve operational challenges facing clinical institutions as radionuclide (RI) therapy rapidly expands, contributing to the realization of a healthcare system in which patients can receive the treatment they need at the appropriate time.

Adopted Project Title
Development of a Toilet-Integrated Urine Purification System to Reduce the Burden on Patients and Healthcare Professionals and Expand Access to Radionuclide Therapy

Research and Development Overview
This R&D initiative focuses on developing a toilet-integrated urine purification system that adsorbs and removes radioactive substances in patient urine following RI therapy — in real time, at the point of urination.
Building on AMS's proprietary adsorption column technology, the system integrates the entire process from urination to treatment in a single unit, eliminating the need for urine collection, transport, and separate disposal. The goal is to significantly reduce the physical burden on patients, the workload of healthcare professionals, and the risk of radiation exposure.
Furthermore, by improving the operational efficiency of special-measures hospital rooms and reducing the institutional burden associated with introducing and operating RI therapy, AMS aims to strengthen the national treatment infrastructure, improve patient access to care, and achieve broader, more equitable delivery of RI therapy across Japan.

Anticipated Social Impact
RI therapy for prostate cancer and neuroendocrine tumors is expanding rapidly on a global scale. At the same time, challenges related to radioactive waste management, healthcare worker burden, and the operation of special-measures rooms represent significant constraints on the capacity to deliver these treatments.
Through this research and development effort, AMS will address these operational barriers and work toward a medical environment in which RI therapy can be delivered more safely and efficiently.

Research and Development Structure
This program will be led by AMS in collaboration with domestic and international specialist institutions.

• •Program Management / Primary Research Institution：AMS
• •Co-Research Institutions：Yokohama City University; Shibaura Institute of Technology
• • Co-Researcher:
  • Shoko Takano, M.D., Ph.D.
  • Department of Nuclear Medicine, Yokohama City University Hospital
  • Prof. Noriko Hashida
  • Functional Control Systems, Department of Engineering and Design, Mechanical Engineering, Shibaura Institute of Technology
• •Advisors：Tokyo Power Technology Ltd.; National Cancer Center Japan; Department of Nuclear Medicine, and one other advisor

Comment from AMS CEO
"RI therapy is an innovative treatment that must reach far more patients in the years ahead. Its broader adoption, however, requires not only access to the drugs themselves, but the development of safe and sustainable medical infrastructure. Through this program, AMS will contribute to reducing the burden on clinical settings and enhancing treatment delivery capacity — accelerating the social implementation of nuclear medicine infrastructure technology, originating from Japan."


AMS's mission is to deliver RI therapy to more patients through the transformation of nuclear medicine infrastructure. The company advances technology development aimed at improving safety, operational efficiency, and access across the field of nuclear medicine.

Grant Amount
Approximately JPY 70 million in funding over a period of two years.

Related Link
FY2026 Go-Tech Program — Adopted Projects Announced (METI Kanto Bureau)
https://www.kanto.meti.go.jp/seisaku/sapoin/r8fy_go-tech_saitaku1.html

About the Go-Tech Program
The Growth-Oriented R&D Support Program for SMEs (Go-Tech Program) is a METI initiative designed to advance foundational manufacturing technologies and services — including precision machining, surface treatment, and three-dimensional fabrication — among small and medium-sized enterprises. The program supports collaborative R&D, prototype development, and market development activities conducted by SMEs in partnership with universities and public research institutions.